Methods and systems for presenting a combination treatment
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G06Q-010/00
G06N-003/00
A61B-005/08
출원번호
US-0315072
(2008-11-26)
등록번호
US-8682687
(2014-03-25)
발명자
/ 주소
Hyde, Roderick A.
Ishikawa, Muriel Y.
Leuthardt, Eric C.
Levien, Royce A.
Lord, Robert W.
Malamud, Mark A.
Sweeney, Elizabeth A.
Wood, Jr., Lowell L.
Wood, Victoria Y. H.
출원인 / 주소
The Invention Science Fund I, LLC
인용정보
피인용 횟수 :
1인용 특허 :
77
초록▼
Methods, computer program products, and systems are described that include accepting an indication of a schedule for administration of a bioactive agent to an individual and presenting an indication of an artificial sensory experience at least partly based on the accepting an indication of the sched
Methods, computer program products, and systems are described that include accepting an indication of a schedule for administration of a bioactive agent to an individual and presenting an indication of an artificial sensory experience at least partly based on the accepting an indication of the schedule for administration of the bioactive agent to the individual.
대표청구항▼
1. A computer-implemented method, comprising: accepting a pharmacokinetic profile of a prescribed bioactive agent;accepting, using a suitable microprocessor, an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual; andpresenting a prescription for
1. A computer-implemented method, comprising: accepting a pharmacokinetic profile of a prescribed bioactive agent;accepting, using a suitable microprocessor, an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual; andpresenting a prescription for engagement of the individual with a virtual experience at at least one time when a concentration of the prescribed bioactive agent is expected to be below a substantially effective level at least partly based on accepting the pharmacokinetic profile of the prescribed bioactive agent and at least partially based on accepting the indication of the prescribed schedule for administration of the prescribed bioactive agent to the individual, the pharmacokinetic profile of the prescribed bioactive agent including at least one or more effective concentration levels of the prescribed bioactive agent. 2. A system, comprising: means for accepting a pharmacokinetic profile of a prescribed bioactive agent;means for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual; andmeans for presenting a prescription for engagement of the individual with a virtual experience at at least one time when a concentration of the prescribed bioactive agent is expected to be below a substantially effective level at least partly based on accepting the pharmacokinetic profile of the prescribed bioactive agent and at least partially based on accepting the indication of the prescribed schedule for administration of the prescribed bioactive agent to the individual, the pharmacokinetic profile of the prescribed bioactive agent including at least one or more effective concentration levels of the prescribed bioactive agent. 3. The system of claim 2, wherein the means for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual comprises: means for accepting a bioactive agent time schedule. 4. The system of claim 2, wherein the means for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual comprises: means for accepting at least one of a bioactive agent delivery type or bioactive agent delivery dosage administration schedule. 5. The system of claim 2, wherein the means for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual comprises: means for accepting a bioactive agent loading dose. 6. The system of claim 2, further comprising: means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent. 7. The system of claim 6, wherein the means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent comprises: means for accepting an indication of a time versus concentration representation for a bioactive agent. 8. The system of claim 6, wherein the means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent comprises: means for accepting an indication of a dose versus response representation for a bioactive agent. 9. The system of claim 6, wherein the means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent comprises: means for accepting a pharmacokinetic model. 10. The system of claim 9, wherein the means for accepting a pharmacokinetic model comprises: means for accepting a physiologically-based pharmacokinetic model. 11. The system of claim 9, wherein the means for accepting a pharmacokinetic model comprises: means for accepting an output from physiologically-based pharmacokinetic modeling software. 12. The system of claim 6, wherein the means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent comprises: means for accepting pharmacokinetic profile information for a bioactive agent including at least one of an absorption characteristic, a distribution characteristic, a metabolization characteristic, or an excretion characteristic. 13. The system of claim 6, wherein the means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent comprises: means for accepting an indication of a pharmacokinetic profile at least partly based on at least one attribute of the individual. 14. The system of claim 6, wherein the means for accepting an indication of at least one of a pharmacokinetic or pharmacodynamic profile of a bioactive agent comprises: means for accepting at least one of a Tmin, Tmax, Cmin, or a Cmax value for the bioactive agent. 15. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for presenting an indication of a prescribed virtual experience. 16. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for utilizing an algorithm for recommending at least one virtual experience. 17. The system of claim 16, wherein the means for utilizing an algorithm for recommending at least one virtual experience comprises: means for utilizing pharmacokinetic modeling software. 18. The system of claim 16, wherein the means for utilizing an algorithm for recommending at least one virtual experience comprises: means for utilizing pharmacodynamic modeling software. 19. The system of claim 16, wherein the means for utilizing an algorithm for recommending at least one virtual experience comprises: means for utilizing an algorithm configured for identifying a contraindication of the virtual experience. 20. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for presenting the prescription for engagement of the individual with the virtual experience at least partly based on a personal medical history. 21. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for presenting the prescription of the individual with the virtual experience at least partly based on experimental data. 22. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for presenting the prescription for engagement of the individual with the virtual experience at least partly based on a medical reference tool. 23. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for presenting the prescription for engagement of the individual with the virtual experience to at least one output device. 24. The system of claim 2, wherein the means for presenting a prescription for engagement of the individual with a virtual experience comprises: means for presenting the prescription for engagement of the individual with the virtual experience to a third party. 25. The system of claim 24, wherein the means for presenting the prescription for engagement of the individual with the virtual experience to a third party comprises: means for presenting the prescription for engagement of the individual with the virtual experience to a health care provider. 26. The system of claim 24, wherein the means for presenting the prescription for engagement of the individual with the virtual experience to a third party comprises: means for selectively presenting the prescription for engagement of the individual with the virtual experience only to the individual. 27. The system of claim 2, wherein the means for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual and means for presenting a prescription for engagement of the individual with a virtual experience at at least one time when a concentration of the prescribed bioactive agent is expected to be below a substantially effective level at least partly based on accepting the pharmacokinetic profile of the prescribed bioactive agent and at least partially based on accepting the indication of the prescribed schedule for administration of the prescribed bioactive agent to the individual comprises: means for accepting the pharmacokinetic profile of immediate release oxycodone, means for accepting a prescribed administration schedule of the immediate release oxycodone to an individual, and means for presenting a prescription for engagement of the individual with a virtual experience at times when the plasma concentration of the immediate release oxycodone is expected to be below a substantially effective level based on the pharmacokinetic profile of the immediate release oxycodone and the prescribed administration schedule of the immediate release oxycodone. 28. A system, comprising: circuitry for accepting a pharmacokinetic profile of a prescribed bioactive agent;circuitry for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual; andcircuitry for presenting a prescription for engagement of the individual with a virtual experience at at least one time when a concentration of the prescribed bioactive agent is expected to be below a substantially effective level at least partly based on accepting the pharmacokinetic profile of the prescribed bioactive agent and at least partially based on accepting the indication of the prescribed schedule for administration of the prescribed bioactive agent to the individual, the pharmacokinetic profile of the prescribed bioactive agent including at least one or more effective concentration levels of the prescribed bioactive agent. 29. A computer program product comprising: a non-transitory signal-bearing medium bearing one or more instructions for accepting a pharmacokinetic profile of a prescribed bioactive agent; one or more instructions for accepting an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual; andone or more instructions for presenting a prescription for engagement of the individual with a virtual experience at at least one time when a concentration of the prescribed bioactive agent is expected to be below a substantially effective level at least partly based on accepting the pharmacokinetic profile of the prescribed bioactive agent and at least partially based on accepting the indication of the prescribed schedule for administration of the prescribed bioactive agent to the individual, the pharmacokinetic profile of the prescribed bioactive agent including at least one or more effective concentration levels of the prescribed bioactive agent. 30. The computer program product of claim 29, wherein the signal-bearing medium includes a computer-readable medium. 31. The computer program product of claim 29, wherein the signal-bearing medium includes a recordable medium. 32. The computer program product of claim 29, wherein the signal-bearing medium includes a communications medium. 33. A system comprising: a computing device; andone or more instructions that when executed on the computing device cause the computing device to at least:accept a pharmacokinetic profile of a prescribed bioactive agent;accept an indication of a prescribed schedule for administration of the prescribed bioactive agent to an individual; andpresent a prescription for engagement of the individual with a virtual experience at at least one time when a concentration of the prescribed bioactive agent is expected to be below a substantially effective level at least partly based on accepting the pharmacokinetic profile of the prescribed bioactive agent and at least partially based on accepting the indication of the prescribed schedule for administration of the prescribed bioactive agent to the individual, the pharmacokinetic profile of the prescribed bioactive agent including at least one or more effective concentration levels of the prescribed bioactive agent. 34. The system of claim 33 wherein the computing device comprises: one or more of a personal digital assistant (PDA), a personal entertainment device, a mobile phone, a laptop computer, a tablet personal computer, a networked computer, a computing system comprised of a cluster of processors, a computing system comprised of a cluster of servers, a workstation computer, and/or a desktop computer. 35. The system of claim 33, wherein the computing device is operable to accept the at least one attribute of the at least one individual and present the indication of the at least one prescription medication and the at least one virtual experience from at least one memory.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (77)
Auer,John A.; Rutledge,Jolyn; Monteleone,Rand J., Apparatus for processing and displaying patient medical information.
Birkner, Charles Christian; ElDahdah, Elias George; Kirkland, Heather Ann; Martinez, David Frederick, Computerized laboratory information management system.
Suffin,Stephen C.; Emory,W. Hamlin; Brandt,Leonard J., Electroencephalography based systems and methods for selecting therapies and predicting outcomes.
Gerald E. Goetz ; Terry Precht ; Eric Krug ; Andrew Fanton ; Joe Keating ; Brian Coppom ; Bradley Thompson ; Brian Hepp, Medication monitoring system and apparatus.
Webster Henry L. ; Barlow Wayne K. ; Briscoe Dennis R. ; Quirante Carmelo G. ; Thomas Scot B., Method and system for continuous sweat collection and analysis.
Leamon, John H.; McDade, Keith E.; Fierro, Joseph M.; Knight, James R.; Charumilind, Jaran; Myers, Jr., Eugene W.; Simpson, John W.; Volkmer, Greg A., Methods of amplifying and sequencing nucleic acids.
Thrall Karla D. (3804 Alder Lake Ct. West Richland WA 99353) Kenny Donald V. (6947 Sparrow La. Worthington OH 43235) Endres George W. R. (2112 Briarwood Ct. Richland WA 99352) Sisk Daniel R. (1211 Ma, Real time chemical exposure and risk monitor.
Agrafiotis Dimitris K. (Exton PA) Bone Roger F. (Bridgewater NJ) Salemme Francis R. (Kennett Square PA) Soll Richard M. (Lawrenceville NJ), System and method of automatically generating chemical compounds with desired properties.
Patton David L. ; Fredlund John R. ; Horwitz Cecelia M. ; Mir Jose M., System and method of managing a psychological state of an individual using images.
Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Combination treatment selection methods and systems.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.